Nvax conversations trial#
That includes product shipments, so manufacturer - this was a funding mechanism to support a number of things, clinical trial development, certainly the Phase 3, some ongoing clinical trials that Filip could make reference to, large scale manufacturing, scale up activities, as well as the manufacturing of doses. Well, so that guidance assumed some ongoing grant revenue coming from the $1.8 billion on this part of that U.S. And that's a number that we’re extremely confident in and backed up with the APAs that have been in place for some time now.Īnd then given that you don't currently have kind of like an official APA signed in the U.S., just to confirm for investors, that guidance assumes no U.S. But for sure, the most significant portion of that is product related revenue, both from a direct revenue perspective on the Novavax side, as well as product related royalty revenue coming from sales of product, whether that's at Serum or a state-buy or any of our other licensee partners. So, as we've talked about before, we don't get into the absolute details of kind of breaking down that number. And then just going to the $4 billion to $5 billion guidance, maybe can you just walk us through one of the different components and make of that guidance in terms of like, public should be expecting in terms of, I guess product sales versus government contracts that you have remainings with OWS? So, we are thrilled with the progress that we have been made, the infrastructure that's in place and executing against all of our strategic plans. We are truly now a global organization, not only in regulatory approvals, but shipping product into Europe, into Australia, Indonesia, South Korea, et cetera.
Nvax conversations update#
I think it was an exciting earnings call, chalk full of a lot of information about where the company is, the accomplishments certainly over - especially over the last several months, but certainly over the last 12 months highlighted in this latest update of the many regulatory approvals that we have across the globe. So, maybe we can just get right into it, and then you can just walk us through the different components that make up this guidance. So obviously, you guys just had your quarterly call last week, issued your 2022 guidance of $4 billion to $5 billion. I'm really excited to have Novavax management, specifically John Trizzino, Chief Operating Officer and Chief Business Officer, as well as Filip Dubovsky, who is the Chief Medical Officer of Novavax. John Trizzino - EVP & Chief Business & Commercial Officerįilip Dubovsky - EVP & Chief Medical OfficerĪll right. ( NASDAQ: NVAX) Cowen 42nd Annual Healthcare Conference Ma9:50 AM ET
0 kommentar(er)
